Io Therapeutics, Inc. is a privately held biopharmaceutical company headquartered in Houston, Texas, with a mission to discover and develop therapeutic compounds targeting nuclear receptors for cancer, neurodegenerative, and autoimmune diseases.
The company focuses on retinoids and rexinoids, small molecule drugs related to retinoic acid, which control gene expression through interaction with nuclear receptors. Their research on nuclear receptors, such as retinoic acid receptors (RARs) and retinoic acid X receptors (RXRs), has contributed to significant advancements in understanding cancer biology, neurodegenerative diseases like Alzheimer's and Parkinson's, and the dysregulation of the immune system in autoimmune diseases.
Generated from the website